Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4506 in Malignant Tumors
NCT07068932Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4506 in cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose Limited Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
SHR-4506
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07068932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068932.